Cellmid Ltd (CDY)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Cellmid Ltd (CDY) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013119
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月27日
◆ページ数:35
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:オーストラリア
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Cellmid Ltd (Cellmid), formerly Medical Therapies Ltd is a developer of therapies and diagnostic tests. The company holds comprehensive portfolio of intellectual property relating to the novel targets midkine and FGF5. It offers products such as midkine ELISA kit, advangen international hair loss products and evolis products. Cellmid is developing three therapeutic programs including AB102 oncology antibody, CAB101 inflammation antibody, and CMK103 cardiac ischemia. The company’s products are used for the treatment and detection of cancers, the treatment of inflammatory, autoimmune diseases, and ischemic heart disease. It markets its products in Australia and Japan. Cellmid is headquartered in Sydney, New South Wales, Australia.

Cellmid Ltd (CDY) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Cellmid Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Cellmid Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Cellmid Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Cellmid Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Cellmid Ltd, Medical Devices Deals, 2011 to YTD 2017 9
Cellmid Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Cellmid Ltd, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Fujikura Kasei Exercises Option For Licensing Agreement With Cellmid For Anti-Midkine Diagnostic Antibodies 11
Cellmid Enters into Agreement with Antitope 12
Licensing Agreements 13
Cellmid Enters into Option Agreement with Zoetis to License Anti-Midkine Antibodies 13
Equity Offering 14
Cellmid Raises USD2.4 Million in First Tranche of Private Placement of Shares 14
Cellmid Completes Private Placement Of Shares For US$1.8 Million 15
Cellmid Completes Private Placement Of Shares For US$2 Million 16
Cellmid Completes Private Placement Of Shares For US$0.3 Million 17
Acquisition 18
Cellmid Completes Acquisition Of Advangen, Biotech Company, For US$1.2 Million 18
Cellmid Ltd – Key Competitors 20
Cellmid Ltd – Key Employees 21
Cellmid Ltd – Locations And Subsidiaries 22
Head Office 22
Other Locations & Subsidiaries 22
Recent Developments 23
Strategy And Business Planning 23
Apr 08, 2016: Cellmid: Midkine Strategy Update 23
Financial Announcements 24
Sep 27, 2017: Cellmid’s FY2017 Results Presentation 24
Feb 25, 2016: Interim Financial Report For the Half-Year Ended 31 December 2015 : Cellmid 25
Corporate Communications 28
Oct 16, 2017: Cellmid Appoints Dr Martin Cross as Non-executive Director 28
Product News 29
Nov 03, 2016: Cellmid: USA Launch of Evolis 29
Jun 14, 2016: Cellmid Launches Evolis Professional Products 30
Mar 02, 2017: Cellmid’s FGF5 Inhibitor Clinical Study Published 31
Other Significant Developments 32
Oct 25, 2017: Cellmid: Notes to the Appendix 4C 32
Oct 10, 2016: Cellmid Records Highest Ever Quarterly Sales For Evolis 33
May 26, 2016: Cellmid provides update on Japanese sale 34
Appendix 35
Methodology 35
About GlobalData 35
Contact Us 35
Disclaimer 35

List of Tables
Cellmid Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Cellmid Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Cellmid Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Cellmid Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Cellmid Ltd, Deals By Therapy Area, 2011 to YTD 2017 8
Cellmid Ltd, Medical Devices Deals, 2011 to YTD 2017 9
Cellmid Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Fujikura Kasei Exercises Option For Licensing Agreement With Cellmid For Anti-Midkine Diagnostic Antibodies 11
Cellmid Enters into Agreement with Antitope 12
Cellmid Enters into Option Agreement with Zoetis to License Anti-Midkine Antibodies 13
Cellmid Raises USD2.4 Million in First Tranche of Private Placement of Shares 14
Cellmid Completes Private Placement Of Shares For US$1.8 Million 15
Cellmid Completes Private Placement Of Shares For US$2 Million 16
Cellmid Completes Private Placement Of Shares For US$0.3 Million 17
Cellmid Completes Acquisition Of Advangen, Biotech Company, For US$1.2 Million 18
Cellmid Ltd, Key Competitors 20
Cellmid Ltd, Key Employees 21
Cellmid Ltd, Subsidiaries 22

★海外企業調査レポート[Cellmid Ltd (CDY)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Philippine National Bank:企業の戦略・SWOT・財務情報
    Philippine National Bank - Strategy, SWOT and Corporate Finance Report Summary Philippine National Bank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • HCA Healthcare Inc (HCA):企業の財務・戦略的SWOT分析
    HCA Healthcare Inc (HCA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Marriott International Inc:企業のM&A・事業提携・投資動向
    Marriott International Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Marriott International Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acqui …
  • Lantheus Medical Imaging Inc:医療機器:M&Aディール及び事業提携情報
    Summary Lantheus Medical Imaging Inc (Lantheus Medical), a subsidiary of Lantheus Holdings, Inc., develops, manufactures, and commercializes diagnostic imaging agents and products for the diagnosis of conditions that affect heart, brain, lungs and other organs using echocardiography and nuclear imag …
  • Fichtner GmbH & Co KG:企業の戦略的SWOT分析
    Fichtner GmbH & Co KG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Ultra Clean Holdings Inc (UCTT):企業の財務・戦略的SWOT分析
    Summary Ultra Clean Holdings Inc (UCH) is a developer and supplier of critical systems and subsystems. The company’s products include precision robotic solutions, gas delivery systems, industrial and automation production equipment, chemical delivery modules, top-plate assemblies, wafer cleaning sub …
  • Sarovar Hotels Private Limited:企業の戦略・SWOT・財務情報
    Sarovar Hotels Private Limited - Strategy, SWOT and Corporate Finance Report Summary Sarovar Hotels Private Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Nanomerics Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Nanomerics Ltd (Nanomerics) is a healthcare solution provider that develops drug delivery solutions for poorly water soluble drugs, nucleic acids and peptides. The company offers products such as METDoloron, METSporine, METAmphizon, METEnkalon, MET undisclosed, MET ocular undiscl, ocular und …
  • Syros Pharmaceuticals Inc (SYRS):製薬・医療:M&Aディール及び事業提携情報
    Summary Syros Pharmaceuticals Inc (Syros) is a biopharmaceutical company that develops medicines for the treatment of cancer, immune-mediated diseases, and other diseases. The company’s pipeline products under clinical trials include SY-1425, an oral, potent and selective RARa agonist that is used t …
  • Strabag SE:企業のM&A・事業提携・投資動向
    Strabag SE - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Strabag SE Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capi …
  • Prudential Financial, Inc.:企業のM&A・事業提携・投資動向
    Prudential Financial, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Prudential Financial, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acqui …
  • U.S. Venture Inc:企業の戦略的SWOT分析
    U.S. Venture Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • Nuformix Plc (NFX):製薬・医療:M&Aディール及び事業提携情報
    Summary Nuformix Plc (Nuformix), formerly Levrett plc, is a pharmaceutical company which develops cocrystal forms of approved small molecules. Its product candidates which are in clinical and pre-clinical development include NXP001, NXP002, and NXP003 for the treatment of oncology supportive care an …
  • DiaSorin SpA (DIA):企業の財務・戦略的SWOT分析
    DiaSorin SpA (DIA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Calgary Scientific Inc:医療機器:M&Aディール及び事業提携情報
    Summary Calgary Scientific Inc (Calgary Scientific) is a medical imaging company that provides research and diagnostic technologies for the medical industry. The company offers ResolutionMD, is a zero-footprint enterprise viewing platform, which is installed in healthcare facilities and used to view …
  • Uranium Energy Corp:企業の戦略・SWOT・財務分析
    Uranium Energy Corp - Strategy, SWOT and Corporate Finance Report Summary Uranium Energy Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Canara Bank:企業の戦略・SWOT・財務分析
    Canara Bank - Strategy, SWOT and Corporate Finance Report Summary Canara Bank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Allergan plc:企業の戦略・SWOT・財務情報
    Allergan plc - Strategy, SWOT and Corporate Finance Report Summary Allergan plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Breckenridge Pharmaceutical Inc-製薬・医療分野:企業M&A・提携分析
    Summary Breckenridge Pharmaceutical Inc (Breckenridge), a subsidiary of Laboratorios Del Dr Esteve SA is a healthcare solution provider that research, develops and markets various generic prescription products. The company provides products including stradiol, oxcarbazepine tablets, methylprednisolo …
  • EnergySolutions, LLC-エネルギー分野:企業M&A・提携分析
    Summary EnergySolutions, LLC (EnergySolutions) is a nuclear services company that provides integrated services and solutions for management of radioactive material. It offers nuclear operations; characterization; decommissioning; decontamination; site closure; transportation; nuclear materials manag …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆